Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1Breast 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 184Mesothelioma, Malignant 183Mesothelioma 145Solid Tumor 135Retinoblastoma 96Solid Tumors 86Advanced Solid Tumor 60Advanced Solid Tumors 50Solid Tumor, Adult 47Hematopoietic and Lymphatic System Neoplasm 47Carcinoma, Non-Small-Cell Lung 42Lung Neoplasms 33Sarcoma 28Hematopoietic and Lymphoid System Neoplasm 23Small Cell Lung Carcinoma 21Pancreatic Neoplasms 20Stomach Neoplasms 19Neuroblastoma 19Melanoma 19Carcinoma, Renal Cell 19Ovarian Neoplasms 18Neoplasms 17Wilms Tumor 15Colorectal Neoplasms 15Breast Neoplasms 15Osteosarcoma 13Solitary Fibrous Tumor, Pleural 12Rhabdomyosarcoma 12Refractory Solid Tumors 12Esophageal Neoplasms 12

Interventions

Leflunomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × PTEN-Altered Advanced Solid Tumors and HER2 Negative Breast Cancer × Other solid neoplasm × Clear all
NCT04997993 2025-06-25

Leflunomide in Patients With PTEN-Altered Advanced Solid Malignancies and HER2 Negative Breast Cancer

Icahn School of Medicine at Mount Sinai

Phase 1 Recruiting
24 enrolled
BreastOther solid neoplasm

PTEN-Altered Advanced Solid Tumors and HER2 Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡